David Pelizzon Sells 10,131 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 10,131 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $23.10, for a total value of $234,026.10. Following the transaction, the director owned 6,526,633 shares in the company, valued at approximately $150,765,222.30. This trade represents a 0.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

OrthoPediatrics Stock Performance

NASDAQ:KIDS opened at $22.80 on Thursday. The stock has a fifty day moving average price of $21.68 and a 200-day moving average price of $18.80. The company has a market cap of $595.31 million, a price-to-earnings ratio of -13.57 and a beta of 0.99. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. OrthoPediatrics Corp. has a fifty-two week low of $14.42 and a fifty-two week high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, equities analysts anticipate that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

OrthoPediatrics News Roundup

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Wall Street’s consensus rating remains Moderate Buy, with an average price target of $26.44. Piper Sandler maintained an Overweight rating and raised its target to $25, while Needham increased its target to $35 and reiterated Buy. OrthoPediatrics analyst coverage
• Positive Sentiment: Several institutions increased their positions during the first half of the year. Millennium Management raised its stake by 55.3%, Goldman Sachs more than doubled its holdings, and institutional investors collectively own approximately 69.05% of outstanding shares.
• Positive Sentiment: OrthoPediatrics recently exceeded quarterly expectations, reporting revenue of $70.51 million versus the $68.21 million consensus estimate and a loss of $0.26 per share, better than the expected $0.30 loss. This suggests operating results are progressing ahead of forecasts, despite the company remaining unprofitable.
• Neutral Sentiment: The reported transactions appear in multiple director, major-shareholder and beneficial-ownership filings, so some disclosures may represent overlapping ownership records rather than separate sales. The reporting holders still controlled roughly 6.53 million shares after the transactions. SEC ownership filing
• Negative Sentiment: Director David Pelizzon and major shareholder Jennifer N. Pritzker reported sales totaling 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. The sales reduced reported ownership by 4.76% and may weigh on sentiment by creating an insider-selling overhang.
• Negative Sentiment: The same ownership group also reported sales of 10,131 shares on September 1 at $23.10, valued at about $234,000 per filing. While the 0.15% reduction is modest, the additional selling reinforces the near-term supply concern. OrthoPediatrics insider sale report

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in KIDS. AIGH Capital Management LLC acquired a new position in shares of OrthoPediatrics in the 2nd quarter valued at about $5,161,000. Wasatch Advisors LP lifted its stake in OrthoPediatrics by 56.6% in the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock valued at $9,865,000 after buying an additional 186,357 shares during the period. Granahan Investment Management LLC boosted its holdings in shares of OrthoPediatrics by 35.1% during the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock worth $14,231,000 after buying an additional 232,760 shares in the last quarter. Roubaix Capital LLC grew its position in shares of OrthoPediatrics by 23.8% during the 1st quarter. Roubaix Capital LLC now owns 290,047 shares of the company’s stock worth $4,603,000 after buying an additional 55,724 shares during the period. Finally, AWM Investment Company Inc. bought a new stake in shares of OrthoPediatrics in the 2nd quarter valued at $4,537,000. 69.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on KIDS shares. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Piper Sandler restated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Needham & Company LLC upped their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Finally, BTIG Research boosted their price target on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.